An increase in prevalence in healthcare settings across the continuum of care over several decades has resulted in MRSA and other multidrug-resistant organisms (MDROs) being given priority as targets of reduction efforts by several regulatory and advisory bodies. These include the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA) and the Centers for Disease Control and Prevention (CDC).
Despite the continued growth of evidence that universal decolonization is more effective than targeted screen and isolate protocols in reducing HAIs, concerns for antibiotic over-use has fostered the reluctance of some to adopt the universal approach. With the availability of a nonantibiotic nasal decolonization alternative, infection preventionists, infectious disease personnel, nursing managers accountable for HAIs on their units, surgeons and other professionals responsible for patient care and safety have reason to re-consider the advantages of universal decolonization. These advantages extend to several areas in which the reduction of MRSA infection and transmission is paramount, most certainly including efforts to reduce the use of CP.
This Whitepaper will discuss:
Nozin® Nasal Sanitizer® antiseptic is clinically proven to reduce Staph aureus nasal carriage without iodine or antibiotics. The leader in nasal decolonization, Nozin is at the forefront of providing innovative infection control solutions in hospitals and healthcare facilities. Nozin patented technology for use by patients and healthcare professionals can help reduce pathogen burden in high-risk areas and lower infection control costs. Based in Maryland, Global Life Technologies Corp. manufactures Nozin product. www.nozin.com
FILL IN THE FORM AND DOWNLOAD TODAY!